<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03420430</url>
  </required_header>
  <id_info>
    <org_study_id>GL-ONC1-021</org_study_id>
    <nct_id>NCT03420430</nct_id>
  </id_info>
  <brief_title>Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care</brief_title>
  <official_title>Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genelux Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genelux Corporation</source>
  <brief_summary>
    <textblock>
      GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical
      trial. Expanded access is intended to treat individual patients with advanced stage cancers,
      including blood cancer, with no standard of care options for treatment. Potential patients
      will be evaluated individually depending on GL-ONC1 product supply.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)</condition>
  <condition>Acute Myeloid Leukemia (6 Patients)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GL-ONC1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of advanced cancers with no standard of care option for treatment.

          -  Willing and able to provide written, signed informed consent.

          -  Use of adequate contraception.

          -  Negative pregnancy test.

        Exclusion Criteria:

          -  Have not recovered from severe adverse events from prior therapy.

          -  Major surgery occurred within 28 days prior to treatment.

          -  Known immune system disorders such as HIV, or active hepatitis B or C infection.

          -  Clinically significant cardiac disease (New York Heart Association Class III or IV).

          -  Have received prior therapy with an oncolytic virus of any type.

          -  Be receiving antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia
             immunoglobulin, imatinib, ST-246).

          -  Have known allergy to ovalbumin or other egg products.

          -  Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any
             unhealed skin wounds or ulcers) as assessed by the treating physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Susan Coakley</last_name>
    <phone>407-303-2090</phone>
    <email>susan.coakley@flhosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Susan Coakley</last_name>
      <phone>407-303-2090</phone>
      <email>susan.coakley@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Ahmed Zakari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.genelux.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

